This is because protein expression is directly proportional to the number of RNA transcripts administered.
- VaxEquity uses self-amplifying RNA which results in generation of multiple RNA copies in the cell and thus greatly enhanced protein expression.
- In addition, VaxEquity, using our proprietary technology platform, can modify the RNA to include elements (innate inhibitory proteins, IIPs) that selectively suppress the innate immune response, thereby preventing the host cell from shutting down RNA replication.
- Use of different IIPs allows for variable control over the innate immune system making VaxEquity’s approach highly tuneable.
VaxEquity’s strategy of administration of saRNA delivering an IIP gives significantly enhanced expression of vaccine antigens or therapeutic proteins. It is highly scalable and stable, and with lower doses being required, more doses can be produced and delivered at a lower price per unit.